Total Funding
26
48
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
241752
Cardax Pharma offers small molecule therapies for unmet medical needs such as hepatitis, arthritis, cardiovascular diseases, and more.
Timothy J. King: Vice President of ResearchPast Role: Hawaii Biotech, Director of Cancer Research
David G. Watumull: Chief Operating OfficerPast Role: Hawaii Biotech, CEO
About the Company
Cardax Pharmaceuticals develops proprietary small molecule therapies for large unmet medical needs where oxidative stress and inflammation play important causative roles—including dyslipidemia, metabolic disease, arthritis, cardiovascular disease, hepatitis, macular degeneration, and many others.
Most anti-inflammatory drugs have significant
safety and side effect issues that limit their utility. In contrast, the company’s proprietary, synthetic, natural compound derivatives represent a novel treatment approach that offers robust efficacy combined with exceptional safety, oral bioavailability, and tissue selectivity.
